Compare Stocks: IMRN, MDXH, KYNB, and RNAZ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMRN Immuron	$1.84 +2.2%	$1.16	$0.68 ▼ $2.39	$14.85M	1.16	854,126 shs	4.11 million shs
KYNB Kyntra Bio	$8.22 -3.9%	$7.40	$6.32 ▼ $12.58	$33.29M	1.06	22,531 shs	11,048 shs
MDXH MDxHealth	$0.71 -4.7%	$0.55	$0.40 ▼ $5.33	$35.32M	1.57	2.46 million shs	325,856 shs
RNAZ TransCode Therapeutics	$1.89 -8.3%	$5.16	$1.83 ▼ $20.99	$32.00M	1.16	124,799 shs	37,454 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMRN Immuron	0.00%	+62.16%	+69.01%	+51.26%	-3.54%
KYNB Kyntra Bio	0.00%	+9.90%	+17.61%	+27.80%	+854,999,900.00%
MDXH MDxHealth	0.00%	+3.92%	+62.34%	+31.46%	-78.80%
RNAZ TransCode Therapeutics	0.00%	-1.90%	-47.98%	-58.63%	-81.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMRN Immuron	$1.84 +2.2%	$1.16	$0.68 ▼ $2.39	$14.85M	1.16	854,126 shs	4.11 million shs
KYNB Kyntra Bio	$8.22 -3.9%	$7.40	$6.32 ▼ $12.58	$33.29M	1.06	22,531 shs	11,048 shs
MDXH MDxHealth	$0.71 -4.7%	$0.55	$0.40 ▼ $5.33	$35.32M	1.57	2.46 million shs	325,856 shs
RNAZ TransCode Therapeutics	$1.89 -8.3%	$5.16	$1.83 ▼ $20.99	$32.00M	1.16	124,799 shs	37,454 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMRN Immuron	0.00%	+62.16%	+69.01%	+51.26%	-3.54%
KYNB Kyntra Bio	0.00%	+9.90%	+17.61%	+27.80%	+854,999,900.00%
MDXH MDxHealth	0.00%	+3.92%	+62.34%	+31.46%	-78.80%
RNAZ TransCode Therapeutics	0.00%	-1.90%	-47.98%	-58.63%	-81.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMRN Immuron	1.00	Sell	N/A	N/A
KYNB Kyntra Bio	2.40	Hold	$36.00	337.96% Upside
MDXH MDxHealth	2.40	Hold	$2.17	203.67% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest IMRN, MDXH, KYNB, and RNAZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	KYNB Kyntra Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/21/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00 ➝ $2.00
8/14/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/14/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$5.00 ➝ $3.00
7/17/2026	RNAZ TransCode Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	KYNB Kyntra Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
6/24/2026	IMRN Immuron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/16/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/9/2026	KYNB Kyntra Bio	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMRN Immuron	$5.47M	2.71	N/A	N/A	$0.93 per share	1.98
KYNB Kyntra Bio	$6.44M	5.17	N/A	N/A	($4.20) per share	-1.96
MDXH MDxHealth	$107.88M	0.33	N/A	N/A	($0.24) per share	-2.97
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMRN Immuron	-$2.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	$183.45M	$45.30	0.18	N/A	N/A	2,199.13%	N/A	-47.27%	N/A
MDXH MDxHealth	-$33.52M	-$0.72	N/A	N/A	N/A	-33.46%	N/A	-24.25%	N/A
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-875.35%	-37.46%	11/18/2026 (Estimated)

Latest IMRN, MDXH, KYNB, and RNAZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q4 2026	IMRN Immuron	N/A	-$0.09	N/A	-$0.0850	N/A	$1.27 million
8/14/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMRN Immuron	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMRN Immuron	N/A	7.17	5.90
KYNB Kyntra Bio	N/A	2.69	2.59
MDXH MDxHealth	N/A	1.15	0.98
RNAZ TransCode Therapeutics	N/A	1.97	1.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMRN Immuron	0.12%
KYNB Kyntra Bio	72.71%
MDXH MDxHealth	N/A
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
IMRN Immuron	7.01%
KYNB Kyntra Bio	4.15%
MDXH MDxHealth	1.70%
RNAZ TransCode Therapeutics	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMRN Immuron	N/A	8.07 million	7.51 million	Not Optionable
KYNB Kyntra Bio	570	4.05 million	3.88 million	N/A
MDXH MDxHealth	300	49.50 million	48.66 million	Not Optionable
RNAZ TransCode Therapeutics	9	16.93 million	16.91 million	Not Optionable

IMRN, MDXH, KYNB, and RNAZ Headlines

Recent News About These Companies

Join TransCode Therapeutics’ Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

September 3, 2026 | usatoday.com

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

August 31, 2026 | prnewswire.com

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

August 7, 2026 | finance.yahoo.com

TransCode Therapeutics, Inc.

July 22, 2026 | edition.cnn.com

TransCode Therapeutics Inc RNAZ

July 3, 2026 | morningstar.comM

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

June 18, 2026 | seekingalpha.com

RNAZ: Introducing RNA therapeutics

June 8, 2026 | msn.com

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

June 8, 2026 | prnewswire.com

RNAZ Share News Today

June 4, 2026 | uk.investing.com

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

June 3, 2026 | finance.yahoo.com

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

June 3, 2026 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 28, 2026 | finanznachrichten.de

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 27, 2026 | prnewswire.com

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

April 27, 2026 | prnewswire.com

TransCode Therapeutics signs financing deal worth up to $20 million

April 8, 2026 | msn.com

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

April 7, 2026 | prnewswire.com

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

March 3, 2026 | prnewswire.com

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

February 23, 2026 | prnewswire.com

TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial

February 11, 2026 | theglobeandmail.com

TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

February 5, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN, MDXH, KYNB, and RNAZ Company Descriptions

Immuron NASDAQ:IMRN

$1.84 +0.04 (+2.22%)

Closing price 04:00 PM Eastern

Extended Trading

$1.87 +0.03 (+1.47%)

As of 05:07 PM Eastern

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Kyntra Bio NASDAQ:KYNB

$8.22 -0.33 (-3.86%)

Closing price 04:00 PM Eastern

Extended Trading

$8.16 -0.06 (-0.67%)

As of 04:10 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

MDxHealth NASDAQ:MDXH

$0.71 -0.03 (-4.66%)

Closing price 04:00 PM Eastern

Extended Trading

$0.70 -0.01 (-1.19%)

As of 05:05 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

TransCode Therapeutics NASDAQ:RNAZ

$1.89 -0.17 (-8.25%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 +0.03 (+1.59%)

As of 05:06 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMRN, MDXH, KYNB, and RNAZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMRN, MDXH, KYNB, and RNAZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMRN, MDXH, KYNB, and RNAZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN, MDXH, KYNB, and RNAZ Company Descriptions

Immuron NASDAQ:IMRN

Kyntra Bio NASDAQ:KYNB

MDxHealth NASDAQ:MDXH

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMRN, MDXH, KYNB, and RNAZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMRN, MDXH, KYNB, and RNAZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMRN, MDXH, KYNB, and RNAZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN, MDXH, KYNB, and RNAZ Company Descriptions

Immuron NASDAQ:IMRN

Kyntra Bio NASDAQ:KYNB

MDxHealth NASDAQ:MDXH

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools